Clinical safety and tolerability of in vivo gene editing drug ART001 for ATTR amyloidosis
Open Access
- 15 April 2026
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 13, 1783921
Abstract
Background: ATTR amyloidosis is a disease caused by abnormal deposition of TTR (transthyretin) protein in tissues. ART001 is an in vivo gene therapy drug using lipid nanoparticle (LNP) to deliver mRNA encoding SpCas9 ( Streptococcus pyogenes Cas9) and a single guide RNA (sgRNA) for knocking-out of the TTR gene in hepatocytes and reducing serum TTR levels. Methods: In an investigator-initiated trial (IIT) of ART001 for 10 ATTR Amyloidosis patients, each patient was given one dose of ART001 which ranged from 0.05 mg/kg to 1.0 mg/kg. The aim was to evaluate ART001’s safety, side effects, PK, PD, and efficacy based on circulating TTR protein levels. Results: At 0.7 mg/kg in 3 subjects and 1 mg/kg in 3 subjects, TTR protein reductions averaged 84 and 92% at 72 weeks. No infusion-related reactions (IRRs), serious adverse events (SAEs) or serious adverse reactions (SARs) were observed. Conclusion: A single injection of ART001 achieved > 80% TTR knock-down at doses > 0.5 mg/kg and lasted for at least 72 weeks without IRRs, SARs or SAEs. ART001 has the potential to be a safe, effective and permanent therapeutic option for ATTR Amyloidosis patients. (Funded by Accuredit Therapeutics). Clinical trial registration: Trial registration: ChiCTR, ChiCTR2400081216. Registered 26 th Feb, 2024 - retrospectively registered, https://www.chictr.org.cn/showprojEN.html?proj=210566 .Keywords
This publication has 22 references indexed in Scilit:
- Eplontersen for Hereditary Transthyretin Amyloidosis With PolyneuropathyJAMA, 2023
- Design and Rationale of the Global Phase 3 NEURO-TTRansform Study of Antisense Oligonucleotide AKCEA-TTR-LRx (ION-682884-CS3) in Hereditary Transthyretin-Mediated Amyloid PolyneuropathyNeurology and Therapy, 2021
- A Single Administration of CRISPR/Cas9 Lipid Nanoparticles Achieves Robust and Persistent In Vivo Genome EditingCell Reports, 2018
- Estimating the global prevalence of transthyretin familial amyloid polyneuropathyMuscle & Nerve, 2018
- Long-term treatment of transthyretin familial amyloid polyneuropathy with tafamidis: a clinical and neurophysiological studyJournal of Neurology, 2016
- Diagnosis, Prognosis, and Therapy of Transthyretin AmyloidosisJACC, 2015
- Repurposing Diflunisal for Familial Amyloid PolyneuropathyJAMA, 2013
- Epidemiology of vitamin A deficiency and xerophthalmia in at-risk populationsTransactions of the Royal Society of Tropical Medicine and Hygiene, 2012
- The effects of glucocorticoids on adipose tissue lipid metabolismMetabolism, 2011
- Reliability and Validity of the Ocular Surface Disease IndexArchives of Ophthalmology (1950), 2000